Radioiodine ablation – current trends and controversies

Author(s): Dr Fahim Ul Hassan

Hospital: Guy's and St Thomas' NHS Foundation Trust

Reference: RAD Magazine, 50, 587, 20-21


Management for differentiated thyroid cancer (DTC) has seen significant changes over the last decade. The approach is dramatically shifting to personalised based rational decisions. This includes, but is not limited to, the extent of surgery, active surveillance in low risk very limited disease, radioiodine (RAI) ablation or no ablation after initial surgery, low iodine activity for remnant ablation, role of post-operative thyroglobulins (Tg)/anti-Tg antibodies for decision making regarding ablation and degree/duration of post-operative thyroid stimulating hormone (TSH) suppression. There is also change in long-term follow-up, a shift from lifelong follow-up to to being discharged in five to 10 years post remission.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more